Education
About Us
Working with TipRanks
Follow Us
Puma Biotechnology (PBYI)
NASDAQ:PBYI
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.09Last Year’s EPS
-0.09Same Quarter Last Year
Moderate Sell
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 18.89%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Neutral
The earnings call presented both positive developments in clinical trials and global expansion efforts, contrasted by significant declines in revenue and sales metrics. The financial challenges, including decreased revenue, prescriptions, and inventory issues, were offset by positive clinical trial results and strategic global partnerships.Company Guidance
During the conference call for the first quarter of 2025, Puma Biotechnology provided guidance on several key financial metrics. The company reported total revenue of $46.0 million, with net product revenue from NERLYNX sales at $43.1 million, a decrease from the previous quarter but an increase from the same quarter last year. Royalty revenue for the quarter was $2.9 million. The company noted a decrease of approximately $4.7 million in inventory at specialty pharmacies and distributors. For fiscal year 2025, Puma anticipates net NERLYNX product revenue to range between $192 million and $198 million, with royalties expected between $20 million and $24 million. The gross to net adjustment for the full year is projected to be between 20.5% and 21.5%. Additionally, Puma forecasts a net income between $23 million and $28 million for the year, with no expected license revenue. For the second quarter of 2025, the company expects NERLYNX net product revenue of $48 million to $50 million and royalty revenue of $2 million to $3 million.Increase in New Prescriptions
New prescriptions for NERLYNX were up approximately 6% compared to Q4 2024.
Expansion of Global Reach
NERLYNX was launched in Libya in the extended adjuvant setting, and a distribution agreement was signed with Er-Kim for select countries in Eastern Europe and Central Asia.
Positive Phase I Trial Data
Interim data from a Phase I trial showed promising results for the combination of neratinib and Fam-trastuzumab deruxtecan in patients with metastatic solid tumors.
Potential for Improved Patient Outcomes
The adoption of dose escalation for NERLYNX patients remains high, with approximately 72% of patients starting at a reduced dose, which is associated with better persistence and compliance.
PBYI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PBYI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $3.07 | $2.91 | -5.21% |
Feb 27, 2025 | $2.99 | $3.58 | +19.73% |
Nov 07, 2024 | $3.03 | $2.88 | -4.95% |
Aug 01, 2024 | $3.50 | $3.83 | +9.43% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Puma Biotechnology (PBYI) report earnings?
Puma Biotechnology (PBYI) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Puma Biotechnology (PBYI) earnings time?
Puma Biotechnology (PBYI) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PBYI EPS forecast?
PBYI EPS forecast for the fiscal quarter 2025 (Q2) is 0.09.